Tylenol Arthritis Extended Relief Name Contested By Aspirin Foundation
This article was originally published in The Tan Sheet
Executive Summary
The Aspirin Foundation of America is challenging the name of McNeil Consumer Healthcare's Tylenol Arthritis Extended Relief as an unapproved, false and misleading efficacy claim that renders the product misbranded.
You may also be interested in...
Tylenol Arthritis Pain Name/Claims Change To Be Reflected In Future Ads
McNeil Consumer Health will alter advertising for Tylenol Arthritis Pain in 2001 to incorporate a revised indication for "pain treatment" in line with a recent FDA decision on a citizen petition submitted by the Aspirin Foundation of America.
Tylenol Arthritis Extended Relief
New name for Tylenol Extended Relief (acetaminophen 650 mg) reflects the fact that about 60% of doctor recommendations for the product have been for the management of arthritis pain, McNeil Consumer Products says Aug. 24. In addition, over 50% of consumers taking Tylenol Extended Relief use it to treat arthritis pain, according to the firm. The new name "will make it easier to find the product on store shelves," McNeil adds. The renamed bi-layer caplets will appear in stores beginning in early September ("The Tan Sheet" July 6, In Brief)...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC